Spots Global Cancer Trial Database for estrogen receptor
Every month we try and update this database with for estrogen receptor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Molecular Triaging of Newly Diagnosed Breast Cancer | NCT01159236 | Breast Cancer | Paclitaxel Fluorouracil Doxorubicin Epirubicin Cyclophosphamid... Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | NCT04137640 | Breast Cancer | palbociclib com... epirubicin comb... | 18 Years - 70 Years | Shengjing Hospital | |
| Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China | NCT03437837 | Breast Cancer Neoadjuvant The... Neoplasm Stagin... Estrogen Recept... Histological Gr... HER2 Prognosis Predictive Valu... | 18 Years - 75 Years | Peking University First Hospital | ||
| A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer | NCT04514159 | Breast Cancer | ZN-c5 Abemaciclib | 18 Years - | Zeno Alpha Inc. | |
| Role of Soy Supplementation in Prostate Cancer Development | NCT00255125 | Prostate Neopla... | Soy Supplement Placebo | 18 Years - | VA Office of Research and Development | |
| Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer | NCT04270149 | Breast Cancer | ESR1 peptide va... | 18 Years - | Duke University | |
| Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy | NCT00897299 | Breast Cancer Estrogen Recept... Her-2 Pgr | microarray anal... protein express... immunohistochem... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes | NCT06115577 | Endometrial Hyp... Endometrial Hyp... Endometrial Can... Peripheral Bloo... Postmenopause Estrogen Recept... Progesterone Re... | endometrial tis... | 53 Years - 80 Years | Pirogov Russian National Research Medical University | |
| Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites | NCT01377324 | Metastatic Brea... | Diagnostic inte... | 18 Years - | University Medical Center Groningen | |
| Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites | NCT01377324 | Metastatic Brea... | Diagnostic inte... | 18 Years - | University Medical Center Groningen | |
| A Study of ZN-c5 in Subjects With Breast Cancer | NCT03560531 | Breast Cancer | ZN-c5 Palbociclib | 18 Years - | Zeno Alpha Inc. | |
| Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer | NCT00210028 | Breast Neoplasm... | Tamoxifen Zarnestra | 18 Years - | Institut Claudius Regaud | |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | NCT06247995 | Breast Cancer | [68Ga]Ga-NeoB [177Lu]Lu-NeoB Capecitabine | 18 Years - | Novartis | |
| Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | NCT04137640 | Breast Cancer | palbociclib com... epirubicin comb... | 18 Years - 70 Years | Shengjing Hospital | |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | NCT06247995 | Breast Cancer | [68Ga]Ga-NeoB [177Lu]Lu-NeoB Capecitabine | 18 Years - | Novartis | |
| Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer | NCT02115594 | Breast Cancer | Fulvestrant Entinostat Placebo | - | Syndax Pharmaceuticals | |
| FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment | NCT03489473 | Endometrial Can... | 18F-FES PET CT ... | 40 Years - | Radboud University Medical Center | |
| Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer | NCT02115594 | Breast Cancer | Fulvestrant Entinostat Placebo | - | Syndax Pharmaceuticals | |
| A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | NCT01216176 | Breast Cancer | Anastrozole AZD0530 (saraca... Placebo | 18 Years - | University of Miami | |
| Role of Soy Supplementation in Prostate Cancer Development | NCT00255125 | Prostate Neopla... | Soy Supplement Placebo | 18 Years - | VA Office of Research and Development | |
| Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics | NCT00612560 | Breast Cancer | Anastrozole flaxseed Placebo | 18 Years - 85 Years | Roswell Park Cancer Institute | |
| PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) | NCT03809988 | Breast Cancer Advanced Breast... Hormone Recepto... Human Epidermal... | Palbociclib Endocrine thera... | 18 Years - | MedSIR | |
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | NCT02734615 | Advanced or Met... | LSZ102 LEE011 BYL719 | 18 Years - | Novartis | |
| Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts | NCT02752893 | Breast Cancer | 18 Years - | Dartmouth-Hitchcock Medical Center | ||
| Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | NCT02820961 | Breast Cancer Estrogen Recept... | entinostat exemestane | 18 Years - 85 Years | Syndax Pharmaceuticals | |
| Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy | NCT00897299 | Breast Cancer Estrogen Recept... Her-2 Pgr | microarray anal... protein express... immunohistochem... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts | NCT02752893 | Breast Cancer | 18 Years - | Dartmouth-Hitchcock Medical Center | ||
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | NCT03250676 | Breast Neoplasm... Breast Cancer Estrogen-recept... Cancer, Breast Breast Cancer F... Breast Adenocar... Estrogen Recept... ER Positive | H3B-6545 | 18 Years - | Eisai Inc. | |
| 18-F-Fluoroacetate as PET Imaging Agent | NCT01320787 | Brain Cancer Breast Cancer Prostate Cancer | 18F-fluoroaceta... | 18 Years - | M.D. Anderson Cancer Center | |
| Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | NCT01197170 | Solid Tumors Advanced Cancer | Anastrozole Bevacizumab Everolimus Sorafenib Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Role of Soy Supplementation in Prostate Cancer Development | NCT00255125 | Prostate Neopla... | Soy Supplement Placebo | 18 Years - | VA Office of Research and Development | |
| Molecular Triaging of Newly Diagnosed Breast Cancer | NCT01159236 | Breast Cancer | Paclitaxel Fluorouracil Doxorubicin Epirubicin Cyclophosphamid... Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer | NCT02482753 | Breast Cancer | Chidamide exemestane placebo | 18 Years - 75 Years | Chipscreen Biosciences, Ltd. | |
| Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer | NCT04270149 | Breast Cancer | ESR1 peptide va... | 18 Years - | Duke University | |
| Nuclear Myosin VI - a Therapeutic Target in Breast Cancer | NCT03430024 | Breast Cancer | Association of ... | 18 Years - 85 Years | Maidstone & Tunbridge Wells NHS Trust | |
| A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | NCT05549505 | Breast Cancer | ARV-471 Anastrozole Surgical resect... | 18 Years - | Arvinas Inc. | |
| Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation | NCT03544762 | Breast Cancer | 18F-FES PET | 20 Years - | National Taiwan University Hospital | |
| Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | NCT03219476 | Breast Cancer Invasive Breast... | Anastrozole Letrozole Exemestane Tamoxifen | 18 Years - | Medical College of Wisconsin | |
| Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression | NCT03870399 | Neuroendocrine ... Progesterone Re... Estrogen Recept... | Tamoxifen | 18 Years - | AC Camargo Cancer Center | |
| Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | NCT04137640 | Breast Cancer | palbociclib com... epirubicin comb... | 18 Years - 70 Years | Shengjing Hospital | |
| Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression | NCT03870399 | Neuroendocrine ... Progesterone Re... Estrogen Recept... | Tamoxifen | 18 Years - | AC Camargo Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
